العلاج الخطي الأول لللمفومة ذات الخلايا الكبيرة اللاتمايزية السلبية لـ ALK

References

DOI: 10.1016/j.annonc.2025.07.014

• First-line treatment of anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL):
• In patients with limited-stage, non-bulky disease and a favourable pre-therapeutic risk profile, abbreviated ChT [e.g. three to four cycles of BV—cyclophosphamide—doxorubicin—prednisolone (BV-CHP) or CHOEP] [III, B] followed by consolidative ISRT (e.g. 30-40 Gy) [IV, B] can be recommended.
• All other ChT-eligible patients should be offered six cycles of BV-CHP [I, A].
• Six cycles of CHO(E)P is an alternative for patients with advanced-stage disease [III, B].
• Consolidative ISRT can be recommended for patients with stage I-II, bulky or IPI >1 disease after six cycles of BV-CHP or CHO(E)P [IV, B].
• Consolidative ASCT in first CR can be considered for transplant-eligible, chemosensitive patients with stage III-IV disease [II, B].